| Ytd | -21.82% | |
| 1y | 71.38% |
| Open | 21.31 | Prev Close | 21.25 | Low | 20.52 | High | 21.75 | Mkt Cap | 436.61M |
| Vol | 339.07K | Avg Vol | 346.89K | EPS | -4.58 | P/E | N/A | Forward P/E | -1.04 |
| Beta | 1.46 | Short Ratio | 0.09 | Inst. Own | 54.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 21.98 | 200-d Avg | 22.68 | 1yr Est | 107.00 |
FBRX News
Forte Biosciences, Inc.$500,000,000Common StockPreferred StockDebt SecuritiesDepositary SharesWarran
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.24) per share which missed the anal
U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa
Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimm
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(1.45) per share which missed the anal
Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Forte Biosciences (NASDAQ:FB
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.99) per share which beat the analys
Additional data continues to support highly differentiated profile for FB102 in celiac diseaseForte
Guggenheim analyst Yatin Suneja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and
Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimm
Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical compa
The Dow Jones index closed higher by over 150 points on Tuesday. When insiders purchase or sell shar
On Tuesday, 647 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
On Friday, 73 companies reached new 52-week lows.
On Tuesday, 123 stocks made new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Tuesday morning saw 454 companies set new 52-week lows.
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its fir
Gainers VivoPower International PLC (NASDAQ: VVPR) shares jumped 69.1% to close at $8.25 on Frida